PBA
SYRE icon

Paradigm Biocapital Advisors’s Spyre Therapeutics SYRE Stock Holding History

Paradigm Biocapital Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$341M Buy
3,840,778
+1,883,512
+96% +$137M 6.38% 5
2026
Q1 		$98.7M Buy
1,957,266
+490,000
+33% +$18.5M 2.02% 16
2025
Q4 		$48.1M Hold
1,467,266
– – 1.23% 20
2025
Q3 		$24.6M Sell
1,467,266
-403,179
-22% -$6.57M 0.7% 31
2025
Q2 		$28M Sell
1,870,445
-256,760
-12% -$3.8M 1.2% 23
2025
Q1 		$34.3M Buy
2,127,205
+600,000
+39% +$12.5M 1.57% 18
2024
Q4 		$35.6M Buy
1,527,205
+259,624
+20% +$7.61M 1.24% 20
2024
Q3 		$37.3M Buy
+1,267,581
New +$35.3M 1.26% 26

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paradigm Biocapital Advisors's SYRE Position: Q2 2026 in Review

Paradigm Biocapital Advisors increased its Spyre Therapeutics (SYRE) stake by 96% in Q2 2026, buying an estimated $137M and bringing the position to 3,840,778 shares worth $341M. The position accounts for 6.38% of the portfolio, ranked #5.

Paradigm Biocapital Advisors first reported a position in SYRE in Q3 2024 and has held it in 8 quarters since. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Paradigm Biocapital Advisors held 3,840,778 shares of Spyre Therapeutics worth $341M as of Q2 2026.
  • Paradigm Biocapital Advisors bought 1,883,512 Spyre Therapeutics shares in Q2 2026, an estimated $137M.
  • Spyre Therapeutics made up 6.38% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #5 holding.
  • Paradigm Biocapital Advisors first reported a position in Spyre Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.